Literature DB >> 1799632

The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU.

S Spinelli1, Q Z Liu, P M Alzari, P H Hirel, R J Poljak.   

Abstract

The crystal structure of the aspartyl protease encoded by the gene pol of the human immunodeficiency virus (HIV-1, isolate BRU) has been determined to 2.7 A resolution. The enzyme, expressed as an insoluble denatured polypeptide in inclusion bodies of Escherichia coli has been renatured and crystallized. It differs by several amino acid replacements from the homologous enzymes of other HIV-1 isolates. A superposition of the C alpha-backbone of the BRU protease with that of the SF2 protease gives a roots mean square positional difference of 0.45 A. Thus, neither the denaturation/renaturation process nor the amino acid replacements have a noticeable effect on the three-dimensional structure of the BRU protease or on the detailed conformation of the catalytic site, which is very similar to that of other aspartyl proteases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1799632     DOI: 10.1016/0300-9084(91)90169-2

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  60 in total

1.  Point mutations and sequence variability in proteins: redistributions of preexisting populations.

Authors:  N Sinha; R Nussinov
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease.

Authors:  J Trylska; J Antosiewicz; M Geller; C N Hodge; R M Klabe; M S Head; M K Gilson
Journal:  Protein Sci       Date:  1999-01       Impact factor: 6.725

3.  A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.

Authors:  Pia Rücker; Anselm H C Horn; Heike Meiselbach; Heinrich Sticht
Journal:  J Mol Model       Date:  2011-01-29       Impact factor: 1.810

4.  Pulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts.

Authors:  Zhanglong Liu; Thomas M Casey; Mandy E Blackburn; Xi Huang; Linh Pham; Ian Mitchelle S de Vera; Jeffrey D Carter; Jamie L Kear-Scott; Angelo M Veloro; Luis Galiano; Gail E Fanucci
Journal:  Phys Chem Chem Phys       Date:  2016-02-17       Impact factor: 3.676

5.  HIV-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state.

Authors:  Viktor Hornak; Asim Okur; Robert C Rizzo; Carlos Simmerling
Journal:  J Am Chem Soc       Date:  2006-03-08       Impact factor: 15.419

6.  Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations.

Authors:  Heike Meiselbach; Anselm H C Horn; Thomas Harrer; Heinrich Sticht
Journal:  J Mol Model       Date:  2006-06-23       Impact factor: 1.810

7.  Gaussian-weighted RMSD superposition of proteins: a structural comparison for flexible proteins and predicted protein structures.

Authors:  Kelly L Damm; Heather A Carlson
Journal:  Biophys J       Date:  2006-03-24       Impact factor: 4.033

8.  HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations.

Authors:  Viktor Hornak; Asim Okur; Robert C Rizzo; Carlos Simmerling
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

9.  Identifying binding hot spots on protein surfaces by mixed-solvent molecular dynamics: HIV-1 protease as a test case.

Authors:  Peter M U Ung; Phani Ghanakota; Sarah E Graham; Katrina W Lexa; Heather A Carlson
Journal:  Biopolymers       Date:  2016-01       Impact factor: 2.505

10.  Effects of Hinge-region Natural Polymorphisms on Human Immunodeficiency Virus-Type 1 Protease Structure, Dynamics, and Drug Pressure Evolution.

Authors:  Zhanglong Liu; Xi Huang; Lingna Hu; Linh Pham; Katye M Poole; Yan Tang; Brian P Mahon; Wenxing Tang; Kunhua Li; Nathan E Goldfarb; Ben M Dunn; Robert McKenna; Gail E Fanucci
Journal:  J Biol Chem       Date:  2016-08-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.